YONKERS, N.Y., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Aureon Laboratories, Inc. today announced the appointment of Robert L. Van Nostrand as Executive Vice President and Chief Financial Officer. Mr. Van Nostrand brings to Aureon an extensive background in the financial and strategic management of healthcare companies. Most recently, he served as Executive Vice President and Chief Financial Officer at AGI Dermatics, Inc., where he helped oversee the company's successful acquisition by a Fortune 500 cosmetics company. Prior to his tenure at AGI Dermatics, Mr. Van Nostrand spent 21 years at OSI Pharmaceuticals, Inc., where he served as Senior Vice President, Chief Compliance Officer and Chief Financial Officer, among other positions. Mr. Van Nostrand remains an active board member for Metabolix, Inc., Achillion Pharmaceuticals, Inc. and is affiliated with numerous organizations including the Association of Biofinance Officers and the New York Biotechnology Association. Mr. Van Nostrand will assume responsibility for all financial aspects of the company's activities.
